// App-Quantinova.ai

1114-200 : MATRIX METALLOPROTEINASE-9 IS ASSOCIATED WITH THE SEVERITY AND MAJOR ADVERSE CARDIOVASCULAR EVENT IN PATIENTS WITH SYSTOLIC HEART FAILURE

Researchers

Presenter

  • Tetsuji Morishita

Principal Investigators

  • Hiroyasu Uzui

  • Kenichiro Arakawa

  • Machiko Koike

  • Yusuke Sato

  • Naoki Amaya

  • Kenichi Kaseno

  • Kentaro Ishida

  • Takehiko Sato

  • Yoshitomo Fukuoka

  • Hiroyuki Ikeda

  • Etsuko Ikeda

  • Ako Fujii

Medical Centers

  • University of Fukui, Fukui, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Systolic dysfunction

  • Congestive heart failure

Biomarkers

  • B-type natriuretic peptide

  • Matrix metallopeptidase 9

  • Matrix metalloproteinase

  • Matrix metalloproteinase 1

  • TIMP Metallopeptidase Inhibitor 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved